Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board (SAB) composed of key opinion leaders in oncolytic viruses and gene therapies. The SAB will work cohesively with the Synthetic Biologics’ leadership team to support the Company’s transformative clinical development strategy and extension into oncology.